Unicycive Therapeutics, Inc. (UNCY): Nasdaq/NYSE listing notice — Unicycive receives Nasdaq notice for failure to meet $35M market value requirement

Unicycive Therapeutics, Inc.

Nasdaq notified Unicycive on May 17, 2023 that common stock MV fell below $35M for 30 consecutive business days.
Company has 180 calendar days, until November 13, 2023, to regain compliance.
If compliance not met by deadline, stock may be delisted; company can appeal to a Hearings Panel.
Unicycive will monitor market value and evaluate options; no assurance of regaining compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Unicycive Therapeutics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

May 17, 2023, Unicycive Therapeutics, Inc. (the “Company”) received written notification (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the market value of the Company’s Common Stock (the “Common Stock”), had closed below the minimum $35 million requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “Minimum Market Value Requirement”). The Notice has no immediate effect on the listing or trading of the Common Stock on the Nasdaq

View on SEC.gov

50 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-042369

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.